[go: up one dir, main page]

AR023308A1 - Uso de dihidropirimidinas para la preparacion de un medicamento, dihidropirimidinas, procedimiento para su produccion y preparados farmaceuticos que loscontienen. - Google Patents

Uso de dihidropirimidinas para la preparacion de un medicamento, dihidropirimidinas, procedimiento para su produccion y preparados farmaceuticos que loscontienen.

Info

Publication number
AR023308A1
AR023308A1 ARP990101778A ARP990101778A AR023308A1 AR 023308 A1 AR023308 A1 AR 023308A1 AR P990101778 A ARP990101778 A AR P990101778A AR P990101778 A ARP990101778 A AR P990101778A AR 023308 A1 AR023308 A1 AR 023308A1
Authority
AR
Argentina
Prior art keywords
alkyl
substituted
hydroxyl
phenyl
halogen
Prior art date
Application number
ARP990101778A
Other languages
English (en)
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of AR023308A1 publication Critical patent/AR023308A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Uso de dihidropirimidinas de formula general 1 o bien de su forma mesomera (1a) en las cuales R1 representa fenilo, furilo, tienilo, triazolilo, piridilo,cicloalquilo C3-6 o representa restos de formulas 2, 3 o 4 estando los sistemas anulares indicados anteriormente eventualmente mono- o multisustituídos porsustituyentes iguales o distintos elegidos del grupo: halogeno, trifluorometilo, nitro, ciano, trifluorometoxi, carboxilo, hidroxilo, alcoxi (C1-6),alcoxicarbonilo (C1-6) y alquilo (C1-6) que, por su parte, puede estar sustituído por arilo con C6-10 o halogeno, y/o los sistemas anulares indicados estáneventualmente sustituídos por grupos de formula -S-R6, NR7R8, CO-NR9R10, SO2-CF3 y -A-CH2-R11, donde R6 significa fenilo que está eventualmente sustituído porhalogeno, R7, R8, R9 y R10 son iguales o distintos y significan hidrogeno, fenilo, fenilo sustituído por hidroxilo, hidroxilo, acilo (C1-6) o alquilo (C1-6)que, por su parte, puede estar sustituído por hidroxilo, alcoxicarbonilo (C1-6), fenilo o fenilo sustituído por hidroxilo, A significa un resto O, S, SO o SO2,R11 significa fenilo que está eventualmente mono- a multisustituído por sustituyentes iguales o distintos elegidos del grupo: halogeno, nitro, trifluorometilo,alquilo (C1-6) y alcoxi (C1-6), R2 representa un resto de formula -XR12 o -NR13R14, donde X significa un enlace u oxígeno, R12 significa hidrogeno,alcoxicarbonilo (C1-6) lineal o ramificado o un resto hidrocarburo (C1-8) lineal, ramificado o cíclico, saturado o insaturado que eventualmente contiene uno odos eslabones heteroátomos iguales o distintos del grupo O, CO, NH, -NH-alquilo (C1-4), -N-(alquilo (C1-4))2, S o SO2 y que está eventualmente sustituído porhalogeno, nitro, ciano, hidroxilo, arilo conC6-10 o arilalquilo con C6-10, heteroarilo o un grupo de formula -NR15R16, donde R15 y R16 son iguales o distintosy significan hidrogeno, bencilo o alquilo (C1-6), R13 y R14 son iguales o distintos y significan hidrogeno, alquilo (C1-6) o cicloalquilo con C3 a 6, R3representa hidrogeno, amino o representa un resto de formula 5, o representa formilo, ciano, alquiltío (C1-6) sustituído por hidroxilo, trifluorometilo o
ARP990101778A 1998-04-18 1999-04-16 Uso de dihidropirimidinas para la preparacion de un medicamento, dihidropirimidinas, procedimiento para su produccion y preparados farmaceuticos que loscontienen. AR023308A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19817265A DE19817265A1 (de) 1998-04-18 1998-04-18 Verwendung von Dihydropyrimidinen als Arzneimittel und neue Stoffe

Publications (1)

Publication Number Publication Date
AR023308A1 true AR023308A1 (es) 2002-09-04

Family

ID=7864973

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990101778A AR023308A1 (es) 1998-04-18 1999-04-16 Uso de dihidropirimidinas para la preparacion de un medicamento, dihidropirimidinas, procedimiento para su produccion y preparados farmaceuticos que loscontienen.

Country Status (12)

Country Link
US (1) US6436943B1 (es)
EP (1) EP1073642B1 (es)
JP (1) JP2002512233A (es)
AR (1) AR023308A1 (es)
AU (1) AU3813499A (es)
CA (1) CA2328733A1 (es)
DE (2) DE19817265A1 (es)
ES (1) ES2186354T3 (es)
GT (1) GT199900054A (es)
PE (1) PE20000426A1 (es)
SV (1) SV1999000048A (es)
WO (1) WO1999054312A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000058302A1 (de) * 1999-03-25 2000-10-05 Bayer Aktiengesellschaft Dihydropyrimidine und ihre verwendung zur behandlung von hepatitis b
EP1193259A4 (en) * 1999-06-23 2003-01-29 Ajinomoto Kk dihydropyrimidine
AU3009801A (en) * 1999-12-22 2001-07-03 Bayer Aktiengesellschaft Combinations of medicaments for treating viral diseases
DE10012549A1 (de) * 2000-03-15 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
DE10012823A1 (de) * 2000-03-16 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
DE10012824A1 (de) * 2000-03-16 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
DE10013126A1 (de) * 2000-03-17 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
GB0201179D0 (en) * 2002-01-18 2002-03-06 Angeletti P Ist Richerche Bio Therapeutic agents
KR100502395B1 (ko) * 2003-06-04 2005-07-19 (주) 비엔씨바이오팜 4-[4-(4-모르포리노)아닐리노]피리미딘 유도체, 그제조방법 및 이를 포함하는 항바이러스용 약학적 조성물.
KR100502394B1 (ko) * 2003-06-04 2005-07-19 (주) 비엔씨바이오팜 2-[2-(4-모르포리노)에틸아미노]피리딘 유도체, 그제조방법 및 이를 포함하는 항바이러스용 약학적 조성물
GB0313250D0 (en) * 2003-06-09 2003-07-16 Angeletti P Ist Richerche Bio Therapeutic agents
PT2514750E (pt) 2007-06-18 2014-01-23 Sunshine Lake Pharma Co Ltd Tiazolil dihidropirimidinas substituídas com bromo-fenilo
AU2008274170B2 (en) 2007-07-12 2011-06-09 Novartis Ag Oral pharmaceutical solutions containing telbivudine
WO2013019967A1 (en) * 2011-08-02 2013-02-07 Scripps Research Institute, A Not-For-Profit Public Benefit Corporation Of California Modulators of virus assembly as antiviral agents
WO2013119895A1 (en) 2012-02-08 2013-08-15 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
US20130267517A1 (en) 2012-03-31 2013-10-10 Hoffmann-La Roche Inc. Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
MY182403A (en) 2012-08-24 2021-01-25 Sunshine Lake Pharma Co Ltd Dihydropyrimidine compounds and their application in pharmaceuticals
AU2013311705A1 (en) 2012-09-10 2015-02-05 F. Hoffmann-La Roche Ag 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of Hepatitis B virus infection
CA2889892A1 (en) * 2012-11-09 2014-05-15 Indiana University Research And Technology Corporation Alternative uses for hbv assembly effectors
KR20150133792A (ko) * 2013-03-20 2015-11-30 인디애나 유니버시티 리서치 앤드 테크놀로지 코포레이션 형광-ｈａｐ: 세포 중의 hbv 코어를 위한 진단 염색제
EP3071564B1 (en) 2013-11-19 2020-08-05 Sunshine Lake Pharma Co., Ltd. Dihydropyrimidine compounds and their application in pharmaceuticals
ES2688600T3 (es) 2013-11-27 2018-11-05 Sunshine Lake Pharma Co., Ltd. Procesos para preparar derivados de dihidropirimidina e intermedios de los mismos
KR20160133563A (ko) 2014-03-28 2016-11-22 선샤인 레이크 파르마 컴퍼니 리미티드 다이하이드로피리미딘 화합물 및 이의 약제학적 용도
TW201629054A (zh) 2015-02-07 2016-08-16 廣東東陽光藥業有限公司 二氫嘧啶衍生物的複合物及其在藥物中的應用
SG10202100751YA (en) 2016-07-29 2021-03-30 Sunovion Pharmaceuticals Inc Compounds and compositions and uses thereof
EA201990400A1 (ru) 2016-07-29 2019-07-31 Суновион Фармасьютикалз, Инк. Соединения и композиции и их применение
CA3058111A1 (en) * 2017-03-31 2018-10-04 Fujifilm Corporation 4-pyridone compound or salt thereof, and pharmaceutical composition and formulation including same
SG11202000669VA (en) 2017-08-02 2020-02-27 Sunovion Pharmaceuticals Inc Isochroman compounds and uses thereof
CN108947996B (zh) * 2018-07-12 2022-01-18 山东大学 二氢嘧啶-磺酰胺类衍生物及其制备方法与应用
CA3130849A1 (en) 2019-03-14 2020-09-17 Sunovion Pharmaceuticals Inc. Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
CN112778299B (zh) * 2019-11-04 2023-07-14 江苏恒瑞医药股份有限公司 哌嗪脲基类衍生物、其制备方法及其在医药上的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH550189A (de) 1971-01-08 1974-06-14 Ciba Geigy Ag Verfahren zur herstellung von neuen dibenzo (b,f) thiepincarbonsaeuren.
CH569043A5 (es) 1973-01-23 1975-11-14 Ciba Geigy Ag
DE3234684A1 (de) 1982-09-18 1984-03-22 Bayer Ag, 5090 Leverkusen Neue dihydropyrimidine, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
US4698340A (en) * 1984-07-19 1987-10-06 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine derivatives, processes for preparation thereof and composition containing the same
US4727073A (en) 1984-10-01 1988-02-23 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine derivatives and composition of the same
JPH07110132B2 (ja) 1991-08-22 1995-11-22 日本モトローラ株式会社 電圧変換装置
JP3349781B2 (ja) 1993-08-30 2002-11-25 富士通株式会社 スイッチングレギュレータ電源装置
US5774319A (en) 1993-10-27 1998-06-30 Square D Company Energy validation arrangement for a self-powered circuit interrupter
US5638264A (en) 1993-12-27 1997-06-10 Hitachi, Ltd. Parallelized power supply system providing uninterrupted operation
JP3493840B2 (ja) 1995-10-27 2004-02-03 松下電工株式会社 電源装置
SE9702564D0 (sv) * 1997-07-02 1997-07-02 Astra Ab New compounds
US5929615A (en) 1998-09-22 1999-07-27 Impala Linear Corporation Step-up/step-down voltage regulator using an MOS synchronous rectifier

Also Published As

Publication number Publication date
ES2186354T3 (es) 2003-05-01
PE20000426A1 (es) 2000-06-25
WO1999054312A1 (de) 1999-10-28
AU3813499A (en) 1999-11-08
EP1073642B1 (de) 2002-10-23
GT199900054A (es) 2000-10-07
CA2328733A1 (en) 1999-10-28
US6436943B1 (en) 2002-08-20
JP2002512233A (ja) 2002-04-23
DE59903174D1 (de) 2002-11-28
DE19817265A1 (de) 1999-10-21
SV1999000048A (es) 2000-07-04
EP1073642A1 (de) 2001-02-07

Similar Documents

Publication Publication Date Title
AR023308A1 (es) Uso de dihidropirimidinas para la preparacion de un medicamento, dihidropirimidinas, procedimiento para su produccion y preparados farmaceuticos que loscontienen.
AR015765A1 (es) Dihidropirimidinas 2 heterociclicamente sustituidas, proceso para su preparacion, medicamentos que los contienen, proceso para la preparacion de los mismosuso de dichos dihidropirimidinas para la preparacion de un medicamento.
AR018175A1 (es) Compuestos de indol-3-glioxilamidas sustituidas, utiles como medicamentos antitumorales, composiciones farmaceuticas formuladas con dichos derivados,utilizacion de dichos derivados para la preparacion de medicamentos antitumorales y los medicamentos asi preparados.
AR016957A1 (es) Derivado de amida y composicion farmaceutica util para la inhibicion del canal de ca2+ activado por liberacion de ca2+
NO930201L (no) Substituerte bicykliske bis-arylforbindelser med selektivleukotrien-b4-antagonistaktivitet, deres fremstilling og bruk
GT200100174A (es) Proceso para la fabricacion de acidos n-aril-antranilicos y sus derivados.
CO5021127A1 (es) Nuevas dihidropirimidas
CO4970713A1 (es) Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
AR065937A2 (es) Compuesto derivado indazol, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para modular la actividad de proteina quinasa
DK0560268T3 (da) Substituerede pipecolinsyrederivater som HIV-proteasehæmmere
AR046781A1 (es) Derivados de imidazoquinolinas. composiciones farmaceuticas.
MX9305379A (es) Nuevos derivados de aminoacidos, procedimiento para su preparacion y preparado farmaceutico que los contiene.
HUP0303652A2 (hu) Ciklikus származékok, mint kemokin receptor aktivitás modulátorai és ezeket tartalmazó gyógyszerkészítmények
TR199800411T1 (xx) T�berk�lozun te�hisi ve imm�noterapi yolu ile �nlenmesine mahsus y�ntemler ve bile�ikler.
AR016010A1 (es) UN COMPUESTO DERIVADO DE ACIDO SULFONHIDROXAMICO AROMATICO INHIBIDOR DE METALOPROTEASAS, COMPUESTO INTERMEDIARIO, PROCESO PARA FORMARLO, COMPOSICION FARMACEUTICA Y USO PARA EL TRATAMIENTO DE UN ANIMAL HUESPED MAMíFERO.
MX162950B (es) Procedimiento para preparar derivados de acidos piridoncarboxilicos
CY1107703T1 (el) Υποκατεστημενες δικετοπιπεραζινες και χρηση αυτων ως ανταγωνιστες οξυτοκινης
MX3277E (es) Procedimiento para la preparacion de derivados de eritromicina
PT753301E (pt) Combinacao de um benzimidazole tendo actividade antagonista da angiotensina ii com um diuretico
CO4700452A1 (es) Derivados de indol
AR066873A1 (es) Derivados de triazolo (1,5-a) quinolina, procesos de obtencion y composiciones farmaceuticas
AR002745A1 (es) 5,6-DIHIDRO-9H-PIRAZOL[3,4-c]-1,2,4-TRIAZOL [4,3-a] PIRIDINAS TRICICLICAS Y COMPOSICIONES FARMACEUTICAS CONTENIENDO LAS MISMAS.
ES2062096T3 (es) Procedimiento para la obtencion de derivados del benzotriazol.
DE3782347D1 (de) Hetaryl-oxy-beta-carbolinderivate, ihre herstellung und verwendung als arzneimittel.
AR043186A1 (es) Indozolamidas dotadas de actividad analgesica, metodo de preparacion de las mismas y compuesto farmaceutico que las comprende